Leonardo Vando
Psychiatry · New York, NYNPI 1225007271
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,532 of the $31,840 with a category attached, or 77.0%. 14 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 35.9% of the total. Reporting peaked in 2019 at $16,692 and has fallen 99.1% since, to $143 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $235.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$11K
- AbbVie$7K
- Sunovion Pharmaceuticals Inc.$7K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$900
- Otsuka Pharmaceutical Development & Commercialization, Inc.$422
- plus $1K from 8 others
Across 611 payments — averaging $1085.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$385K
- Indivior Inc.$222K
- Orexo US, Inc.$26K
- Pear Therapeutics (US), Inc.$22K
- Abbott$8K
What the payments were for
- Consulting fees$2,9989%
- Speaking & faculty fees$24,53277%
- Travel & lodging$8113%
- Food & beverage$3,49911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $11,425 |
| AbbVie(2 entities) | 18 | $7,370 |
| Sunovion Pharmaceuticals Inc. | 34 | $7,361 |
| Teva Pharmaceuticals USA, Inc. | 7 | $3,347 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $900 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $422 |
| Axsome Therapeutics, Inc. | 2 | $293 |
| Johnson & Johnson | 6 | $163 |
| Alkermes, Inc. | 2 | $132 |
| Neurocrine Biosciences, Inc. | 5 | $116 |
| Orexo US, Inc. | 7 | $109 |
| Lundbeck LLC | 5 | $101 |
| Avanir Pharmaceuticals, Inc. | 3 | $60 |
| Acorda Therapeutics, Inc | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$11,101
- VRAYLAR$7,200
- LATUDA$6,879
- CAPLYTA$900
- ARISTADA$464
- Auvelity$293
- Austedo XR$229
- ARISTADA INITIO$116
- ABILIFY MYCITE$107
How this compares
$31,840 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $42,984 |
| RexultiBrexpiprazole | 11 | $15,925 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 109 | $14,271 |
| FetzimaLevomilnacipran Hcl | 28 | $13,135 |
| Lurasidone Hcl | 34 | $12,026 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| SavellaMilnacipran Hcl | 12 | $2,802 |
| Haloperidol Decanoate | 32 | $2,008 |
| Aripiprazole | 57 | $1,039 |
| Clozapine | 25 | $945 |
| Divalproex Sodium ErDivalproex Sodium | 22 | $842 |
| Quetiapine Fumarate | 131 | $829 |
| Naltrexone Hcl | 21 | $751 |
| Haloperidol | 20 | $743 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 49 | $659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $163 | $42,98413 claims |
| AbbVieFetzima, Savella | $7,370 | $15,93740 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $11,425 | $15,92511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.